(Press-News.org) Implementing human papillomavirus (HPV)-based screening in British Columbia could eliminate cervical cancer in the province before 2040, according to a modelling study in CMAJ (Canadian Medical Association Journal) https://www.cmaj.ca/lookup/doi/10.1503/cmaj.231682.
More than 90% of cervical cancer cases worldwide are caused by 9 types of high-risk HPV. The World Health Organization and the Canadian Partnership Against Cancer (CPAC) have both set targets to eliminate cervical cancer by 2040, defined as an annual rate of less than 4 per 100 000 women.
The Pap test has been the primary screening tool for decades, but HPV-based screening shows better accuracy in detecting cervical precancer. As well, HPV-based screening can be performed on samples collected by the patient rather than a health care provider, increasing access and uptake.
“The option for self-collection may also reduce barriers to access and increase screening uptake among those who are never- or underscreened,” writes lead author Dr. Reka Pataky, Canadian Centre for Applied Research in Cancer Control and BC Cancer, Vancouver, BC, with coauthors.
Researchers used CPAC’s OncoSim-Cervical model to develop scenarios that would help BC achieve targets to eliminate cervical cancer. Using current Pap testing, with no changes to HPV vaccination rates or screening participation rates, BC would not reach the goal of 4 cases/100 000 until 2045. If it implemented HPV-based screening, BC would achieve the target by 2034 and prevent more than 900 cases of cervical cancer by 2050.
There are concerns about increased demand for colposcopy to investigate an abnormal result, and precancer treatments with implementation of HPV-based screening. The authors suggest that phased-in HPV testing by age could help reduce the burden on health care systems.
“Screening programs across Canada need to implement HPV-based cervix screening in strategic and innovative ways that increase access to screening services, enhance timely follow-up and treatment, and reduce health disparities across the population,” they conclude.
In a related editorialhttps://www.cmaj.ca/lookup/doi/10.1503/cmaj.240722, Dr. Shannon Charlebois, medical editor at CMAJ, and Dr. Sarah Kean, a gynecologic oncologist at the University of Manitoba, write that cervical cancer is increasing in younger populations and commonly affects equity-seeking groups.
“Invasive cervical cancer disproportionately affects equity-seeking populations,” they write. “Yet, those most at risk are the least likely to be screened, including 2SLGBTQI+ people, immigrants, those with a disability, Black and Indigenous people, and victims of sexual trauma. It is the most common cancer among females living with HIV.”
Self-sampling, which evidence shows is as accurate as physician-collected samples, will help increase access to cervical cancer screening for these groups.
“If Canada is to eliminate cervical cancer, which is entirely possible, every health system across the country should integrate self-sampling into their cervical cancer screening program.”
END
HPV-based screening can help eliminate cervical cancer
2024-06-03
ELSE PRESS RELEASES FROM THIS DATE:
New biomarkers will enable personalised influenza vaccination schedule
2024-06-03
Berlin, Germany: While influenza infection is a significant public health threat, causing serious illness in between three and five million people worldwide per year and leading to about up to 650,000 deaths, the effectiveness of influenza vaccines varies considerably between individuals depending on vaccine types and individual circumstances. A person’s ability to resist infection (host immunity) plays an important role in this. Now, researchers have developed a way of classifying host immunity in individuals, which may lead to the early identification of those who will not respond well to a regular vaccine schedule and therefore ...
Understanding how abnormal embryos self-correct may provide women with a better chance of IVF pregnancy
2024-06-03
Berlin, Germany: Aneuploidy (the presence of an abnormal number of chromosomes) in embryos is a major cause of impaired embryo development, leading to conditions such as Down syndrome, as well as to pregnancy loss. The transfer of such embryos in women undergoing IVF is therefore usually avoided because of unfavourable pregnancy outcomes. But mosaic embryos, comprising both genetically normal and abnormal cells, can result in perfectly normal babies. Now, researchers have been able to understand how these mosaic ...
Metformin may be as safe as insulin during pregnancy, 11-year data shows
2024-06-02
BOSTON—Metformin is safe to use during pregnancy to manage diabetes, with no long-term adverse effects on the children born and their mothers for at least 11 years after childbirth, according to research presented Sunday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass. This is the first study to look at longer term effects of metformin use during pregnancy.
“Metformin has been extensively used for managing raised blood glucose values in pregnancy for many decades now. It is the only blood glucose-lowering oral medication approved ...
Two medication classes reduced cardiovascular and liver events in people with type 2 diabetes
2024-06-02
BOSTON—GLP-1 receptor agonists (GLP-1s) and SGLT-2 inhibitors lower the risk of major cardiovascular events like heart attacks and severe liver complications compared to other diabetes treatments, according to data being presented Sunday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.
“Before this study, there was limited information about how these specific diabetes medications work in patients with both type 2 diabetes and metabolic dysfunction-associated steatotic liver disease (MASLD),” said Alexander Kutz, M.D., M.P.H., M.Sc., a research fellow in the Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, at Brigham ...
Neoadjuvant Immunotherapy for early stage melanoma shows positive results
2024-06-02
Immunotherapy before surgery for patients with metastatic melanoma appears to be especially successful. Fifty-nine percent of patients responds so well to this therapy that adjuvant treatment is no longer needed, according to the results of the NADINA study that were published today.
The NADINA study, led by researchers from the Netherlands Cancer Institute, was named one of the eleven clinical studies with the biggest impact on health care in 2024 by Nature Medicine. The study now proves that this was not an empty claim, as shown by the results presented by medical oncologist and research leader Christian Blank today during ASCO 2024, the international congress ...
CDC reports its decade-long efforts in standardizing vitamin D tests
2024-06-02
BOSTON—Vitamin D tests certified by the U.S. Centers for Disease Control and Prevention (CDC) Clinical Standardization Programs (CSP) are well calibrated overall, according to a new study presented Sunday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass. However, the researchers found some inaccuracies among the assays studied.
The blood tests show an “appropriate” level of analytical accuracy, said the study’s lead researcher, Otoe Sugahara, manager of the CDC Vitamin D Standardization-Certification Program (VDSCP) in Atlanta, Ga.
Analytical accuracy is the test’s ability to correctly analyze vitamin D in this ...
Persons of nonbinary gender may desire lower-dose testosterone treatment than guidelines recommend
2024-06-02
BOSTON—Among transgender and gender-diverse adults whose gender identity is nonbinary—not exclusively male or female—and who choose low-dose hormone treatment, most prefer to continue testosterone therapy at lower-than-recommended doses after at least six months of treatment, a new study finds. The study will be presented Sunday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.
“Current guidelines for initiation of testosterone for gender affirmation assume that transgender and gender-diverse, or trans, individuals desire both rapid and complete masculinization,” ...
High insulin levels contribute to worse outcomes for Black women with aggressive form of breast cancer
2024-06-02
BOSTON—High insulin levels contribute to worse outcomes for Black women compared to white women who have an aggressive form of breast cancer called triple-negative breast cancer, according to a study presented Sunday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.
Triple-negative breast cancer accounts for about 10-15% of all breast cancers. The term triple-negative breast cancer refers to the fact that the cancer cells do not have estrogen or progesterone receptors and do not make any or too much of the protein called HER2. The cells test ‘negative’ on all 3 tests. Triple-negative breast ...
Stress from living in violent neighborhoods tied to aggressive lung cancer in Black men
2024-06-02
BOSTON—Exposure to increased neighborhood violence has the power to change the glucocorticoid receptor (GR) for the stress hormone, cortisol, which may influence the aggressiveness of lung cancer, according to data presented Sunday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.
“This research uncovers a previously unknown link between exposure to neighborhood violence, GR and lung tumor aggressiveness that can help us understand and fix the lung cancer health disparity seen in Black men” said Hannah Heath, B.S., a graduate research assistant ...
Thyroid eye disease patients report maintained improvement 2 years after teprotumumab infusions
2024-06-02
BOSTON—Most patients with thyroid eye disease treated with teprotumumab didn’t require additional treatments nearly 2 years later, according to industry-supported research being presented Sunday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass., and published in the journal Thyroid.
“Thyroid eye disease is a lifelong autoimmune disease that can worsen or flare, regardless of how it has been treated. This is the case for many autoimmune diseases,” said George Kahaly, M.D., Ph.D., professor of medicine and endocrinology at Johannes Gutenberg University Medical Center in Mainz, Germany. “Given the enduring nature ...